Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

However, tirzepatide was more likely to help participants achieve major weight-loss milestones. Nearly one-third (32%) of participants experienced a 25% or more body weight reduction due to ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

CHICAGO — In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according to new data from the SURMOUNT-1 study. As Healio previously ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy ...